ABG WTT Global Life Science Capital Partners GP Ltd Has $4.88 Million Stock Holdings in Rapid Micro Biosystems, Inc. $RPID

Key Points

• ABG WTT Global Life Science Capital Partners GP Ltd increased its stake in Rapid Micro Biosystems by 78.0%, holding 1,848,296 shares after buying an additional 810,000 shares.
• CEO Robert G. Jr. Spignesi sold 11,881 shares of the company at an average price of $3.32, reducing his holdings by 1.21% to 970,550 shares valued at about $3.22 million.
• Equities research analysts have a consensus rating of "Strong Buy" for Rapid Micro Biosystems, with a price target of $8.00 per share.

ABG WTT Global Life Science Capital Partners GP Ltd increased its holdings in Rapid Micro Biosystems, Inc. (NASDAQ:RPID - Free Report) by 78.0% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,848,296 shares of the company's stock after purchasing an additional 810,000 shares during the period. Rapid Micro Biosystems makes up about 12.7% of ABG WTT Global Life Science Capital Partners GP Ltd's holdings, making the stock its 3rd biggest holding. ABG WTT Global Life Science Capital Partners GP Ltd owned approximately 4.27% of Rapid Micro Biosystems worth $4,880,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. American Century Companies Inc. purchased a new stake in Rapid Micro Biosystems during the 1st quarter valued at $31,000. Legato Capital Management LLC purchased a new stake in Rapid Micro Biosystems during the 1st quarter valued at $41,000. Millennium Management LLC boosted its position in Rapid Micro Biosystems by 17.6% during the 4th quarter. Millennium Management LLC now owns 61,375 shares of the company's stock valued at $55,000 after buying an additional 9,191 shares during the period. Essex Investment Management Co. LLC purchased a new stake in Rapid Micro Biosystems during the 1st quarter valued at $166,000. Finally, Citadel Advisors LLC purchased a new stake in Rapid Micro Biosystems during the 4th quarter valued at $65,000. Hedge funds and other institutional investors own 52.60% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on RPID shares. Lake Street Capital started coverage on shares of Rapid Micro Biosystems in a research report on Monday, July 28th. They issued a "buy" rating and a $8.00 target price for the company. Wall Street Zen cut shares of Rapid Micro Biosystems from a "hold" rating to a "sell" rating in a research report on Friday, August 22nd. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Strong Buy" and an average target price of $8.00.

Insider Transactions at Rapid Micro Biosystems

In related news, CEO Robert G. Jr. Spignesi sold 11,881 shares of the business's stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $3.32, for a total transaction of $39,444.92. Following the completion of the sale, the chief executive officer directly owned 970,550 shares in the company, valued at approximately $3,222,226. The trade was a 1.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold 57,443 shares of company stock worth $195,952 in the last three months. Insiders own 29.96% of the company's stock.

Rapid Micro Biosystems Stock Performance

Shares of RPID traded up $0.28 during mid-day trading on Friday, hitting $2.72. 86,902 shares of the company traded hands, compared to its average volume of 89,189. The stock has a 50-day moving average price of $3.18 and a two-hundred day moving average price of $2.94. Rapid Micro Biosystems, Inc. has a 1 year low of $0.80 and a 1 year high of $4.50. The stock has a market cap of $120.25 million, a price-to-earnings ratio of -2.69 and a beta of 1.29.

Rapid Micro Biosystems (NASDAQ:RPID - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.01). The company had revenue of $7.26 million for the quarter, compared to analysts' expectations of $7.10 million. Rapid Micro Biosystems had a negative net margin of 145.63% and a negative return on equity of 63.07%. Rapid Micro Biosystems has set its FY 2025 guidance at EPS. On average, analysts forecast that Rapid Micro Biosystems, Inc. will post -1.1 EPS for the current year.

Rapid Micro Biosystems Profile

Rapid Micro Biosystems, Inc, a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and customer support and validation services.